New shot aims to clear hepatitis b virus in Long-Term patients
NCT ID NCT07190742
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This Phase 2 trial tests an injection called TVAX-008 in 80 adults with chronic hepatitis B who are already on antiviral pills. Half get TVAX-008 plus their usual medication, half get a placebo plus their usual medication, for 24 weeks. The goal is to see if TVAX-008 can make the hepatitis B surface antigen disappear, which would mean better control of the infection.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TVAX-008 injection
What this could lead to
If successful, TVAX-008 could help some people with chronic hepatitis B clear the virus surface antigen, potentially leading to better disease control.
What could go wrong
This is a small, early Phase 2 trial with only 80 participants. The treatment may not work better than placebo, and long-term safety is not yet known.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University first hospital
Beijing, 10000, China